ADVERTISEMENT
Abbott India Q1 Results Review - Soft Quarter; Margin Profile Intact: ICICI Securities
The company may continue to outperform other MNC pharma companies with likely revenue and PAT compound annual growth rates of 10.7% and 16.9% over FY24-26E, says the brokerage.
09 Aug 2024, 04:16 PM IST 
Save
(Source: Abbott India website)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
